Opus Genetics マネジメント

マネジメント基準チェック /24

Opus Geneticsの CEO はGeorge Magrathで、 Nov2023年に任命され、の在任期間は 1.5年です。の年間総報酬は$ 889.24Kで、 64.7%給与と35.3%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の1.52%を直接所有しており、その価値は$ 705.13K 。経営陣と取締役会の平均在任期間はそれぞれ1.4年と4.5年です。

主要情報

George Magrath

最高経営責任者

US$889.2k

報酬総額

CEO給与比率	64.66%
CEO在任期間	1.5yrs
CEOの所有権	1.5%
経営陣の平均在職期間	1.4yrs
取締役会の平均在任期間	4.5yrs

経営陣の近況

Recent updates

Analysts Are Upgrading Opus Genetics, Inc. (NASDAQ:IRD) After Its Latest Results

May 19

Slammed 25% Opus Genetics, Inc. (NASDAQ:IRD) Screens Well Here But There Might Be A Catch

Apr 09

Analyst Forecasts For Ocuphire Pharma, Inc. (NASDAQ:OCUP) Are Surging Higher

Aug 19

Investors Still Aren't Entirely Convinced By Ocuphire Pharma, Inc.'s (NASDAQ:OCUP) Revenues Despite 30% Price Jump

Jul 24

Companies Like Ocuphire Pharma (NASDAQ:OCUP) Are In A Position To Invest In Growth

Jul 12

Slammed 26% Ocuphire Pharma, Inc. (NASDAQ:OCUP) Screens Well Here But There Might Be A Catch

May 02

Ocuphire Pharma, Inc. (NASDAQ:OCUP) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely

Mar 15

Analysts Just Shaved Their Ocuphire Pharma, Inc. (NASDAQ:OCUP) Forecasts Dramatically

May 20

Ocuphire completes patient enrollment for phase 2 trial of diabetic retinopathy treatment

Sep 08

Ocuphire Pharma GAAP EPS of -$0.25 beats by $0.08

Aug 12

Ocuphire extends IP rights for lead candidate with new U.S. patent

Aug 03

Ocuphire gets new U.S. patent for its oral drug candidate APX3330 for use in diabetics

Jun 29

We're Keeping An Eye On Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Rate

Jun 24

CEO報酬分析

Opus Genetics の収益と比較して、George Magrath の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2025	n/a	n/a	-US$59m
Dec 31 2024	US$889k	US$575k	-US$58m
Sep 30 2024	n/a	n/a	-US$27m
Jun 30 2024	n/a	n/a	-US$14m
Mar 31 2024	n/a	n/a	-US$11m
Dec 31 2023	US$3m	US$96k	-US$10m

報酬と市場: Georgeの総報酬 ($USD 889.24K ) は、 US市場 ($USD 647.92K ) の同規模の企業の平均を上回っています。

報酬と収益: Georgeの報酬は、過去 1 年間の会社の業績と一致しています。

CEO

George Magrath (40 yo)

1.5yrs

在職期間

US$889,238

報酬

Mr. George Magrath, MD, MBA, Ms. serves as CEO & Director of Opus Genetics, Inc. (formerly known as Ocuphire Pharma, Inc.) since November 1, 2023. He was an Analyst at Edison Investment Research Limited si...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
George Magrath	CEO & Director	1.5yrs	US$889.24k	1.52% $ 705.1k
Benjamin Yerxa	President & Director	less than a year	データなし	0.022% $ 10.2k
Nirav Suresh Jhaveri	Chief Financial Officer	1.3yrs	US$1.39m	0.081% $ 37.5k
Ashwath Jayagopal	Chief Scientific & Development Officer	1.3yrs	US$1.24m	0.037% $ 17.4k
Joseph Schachle	Chief Operating Officer	1.5yrs	データなし	0.0044% $ 2.0k
Bernhard Hoffmann	Senior Vice President of Corporate Development & Secretary	no data	US$789.92k	0.26% $ 120.0k
Amy Zaremba Rabourn	Senior Vice President of Finance	no data	US$789.92k	0.047% $ 21.6k
Bindu Manne	Head of Market Development & Commercialization	3.3yrs	データなし	データなし
Erik Sims	Director & Corporate Controller	no data	データなし	データなし

1.4yrs

平均在職期間

46yo

平均年齢

経験豊富な経営陣: IRDの経営陣は経験豊富とはみなされません ( 1.4年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
George Magrath	CEO & Director	1.5yrs	US$889.24k	1.52% $ 705.1k
Benjamin Yerxa	President & Director	no data	データなし	0.022% $ 10.2k
James S. Manuso	Independent Director	4.5yrs	US$184.43k	0.31% $ 143.9k
Adrienne Graves	Independent Director	less than a year	US$192.82k	データなし
David Boyer	Member of Medical Advisory Board	no data	データなし	データなし
Richard Rodgers	Independent Director	4.5yrs	US$267.48k	0.53% $ 243.9k
Susan Benton	Independent Director	4.5yrs	US$176.39k	0.31% $ 142.8k
Cameron Gallagher	Independent Chairman	4.5yrs	US$219.61k	1.89% $ 878.6k
Sean Ainsworth	Lead Independent Director	4.5yrs	US$200.22k	0.10% $ 48.2k
Jean Bennett	Director	less than a year	US$325.82k	0.075% $ 34.7k
Arshad Khanani	Member of Medical Advisory Board	1.2yrs	データなし	データなし
Mark Pennesi	Member of Medical Advisory Board	no data	データなし	データなし

4.5yrs

平均在職期間

57.5yo

平均年齢

経験豊富なボード: IRDの取締役会は経験豊富であると考えられます ( 4.5年の平均在任期間)。

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2025/05/19 12:25
終値	2025/05/19 00:00
収益	2025/03/31
年間収益	2024/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Opus Genetics, Inc. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。4

アナリスト	機関
James Molloy	Alliance Global Partners
Gum-Ming Lowe	Craig-Hallum Capital Group LLC
Matthew Caufield	H.C. Wainwright & Co.

Opus Genetics マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Opus Genetics, Inc., Annual General Meeting, Apr 30, 2025

Opus Genetics, Inc. Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs

CEO & Director recently bought US$98k worth of stock

CEO & Director recently bought US$101k worth of stock

Ocuphire Pharma, Inc., Annual General Meeting, Jun 11, 2024

Ocuphire Pharma, Inc. Announces Appointments of Nirav Jhaveri, C.F.A., M.B.A. as Chief Financial Officer

Recent updates

Analysts Are Upgrading Opus Genetics, Inc. (NASDAQ:IRD) After Its Latest Results

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate

Opus Genetics Announces One-Year Results from Adult Patients Treated in the Ongoing Phase 1/2 Study of Its Lead Gene Therapy Candidate OPGx-LCA5

Price target decreased by 13% to US$9.25

Slammed 25% Opus Genetics, Inc. (NASDAQ:IRD) Screens Well Here But There Might Be A Catch

Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases

Consensus revenue estimates increase by 34%

Opus Genetics, Inc. has completed a Follow-on Equity Offering in the amount of $5.2 million.

Opus Genetics, Inc., Annual General Meeting, Apr 30, 2025

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Shareholder dilution

Opus Genetics, Inc. announced that it has received $1.500001 million in funding

Opus Genetics, Inc. has completed a Follow-on Equity Offering in the amount of $19.999999 million.

Opus Genetics, Inc. Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025

Opus Genetics, Inc. Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs

Opus Genetics, Inc. Announces First Pediatric Patient Was Dosed in its Ongoing Phase 1/2 Clinical Trial Evaluating OPGx-LCA5, its Investigational Gene Therapy for the Treatment of Leber Congenital Amaurosis

New major risk - Shareholder dilution

Opus Genetics, Inc. has filed a Follow-on Equity Offering in the amount of $40 million.

CEO & Director recently bought US$98k worth of stock

Opus Genetics, Inc. to Host Virtual KOL Event on OPGx-LCA5 as a Treatment for LCA5-Associated Inherited Retinal Disease on December 11, 2024

CEO & Director recently bought US$101k worth of stock

Consensus revenue estimates increase by 40%, EPS downgraded

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 21% to US$13.67

Ocuphire Pharma, Inc. (NasdaqCM:OCUP) acquired Opus Genetics, Inc. for $25.8 million.

Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology

Analyst Forecasts For Ocuphire Pharma, Inc. (NASDAQ:OCUP) Are Surging Higher

Consensus revenue estimates increase by 62%

Second quarter 2024 earnings: EPS in line with expectations, revenues disappoint

Price target decreased by 12% to US$17.25

Investors Still Aren't Entirely Convinced By Ocuphire Pharma, Inc.'s (NASDAQ:OCUP) Revenues Despite 30% Price Jump

Companies Like Ocuphire Pharma (NASDAQ:OCUP) Are In A Position To Invest In Growth

Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy At Retina Meetings in June

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Slammed 26% Ocuphire Pharma, Inc. (NASDAQ:OCUP) Screens Well Here But There Might Be A Catch

Ocuphire Pharma, Inc., Annual General Meeting, Jun 11, 2024

Ocuphire Pharma, Inc. Announces the Enrollment of the First Subject in the LYNX-2 Phase 3 registration study

Ocuphire Pharma, Inc. (NASDAQ:OCUP) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely

Full year 2023 earnings: EPS and revenues miss analyst expectations

Ocuphire Pharma, Inc. Announces Appointments of Nirav Jhaveri, C.F.A., M.B.A. as Chief Financial Officer

Ocuphire Pharma, Inc. Announces Presentation of Clinical Data from Its ZETA-1 Trial on A Person-Level Scale Evaluating APX3330 in Diabetic Retinopathy

Ocuphire Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Investor sentiment improves as stock rises 17%

Ocuphire Pharma, Inc. Promotes Ronil Patel to Chief Business Officer, Effective as of December 1, 2023

Insufficient new directors

Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer

Consensus revenue estimates increase by 24%

New minor risk - Shareholder dilution

Ocuphire Pharma, Inc. Announces Chief Executive Officer Changes

Investor sentiment deteriorates as stock falls 16%

Viatris Inc. and Ocuphire Pharma, Inc. Announce Fda Approval of Ryzumvl™? (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (E.G., Tropicamide) Agents

New major risk - Revenue and earnings growth

Ocuphire Pharma, Inc. to Present at American Society of Retina Specialists Annual Meeting and OIS Retina Innovation Summit

Ocuphire Pharma, Inc. Presents APX3330 ZETA-1 Clinical Data in Late-Breaker Session at the American Diabetes Association's Annual Conference

Investor sentiment deteriorates as stock falls 19%

Consensus revenue estimates fall by 15%

Analysts Just Shaved Their Ocuphire Pharma, Inc. (NASDAQ:OCUP) Forecasts Dramatically

Price target decreased by 7.8% to US$20.75

Investor sentiment deteriorates as stock falls 18%

Investor sentiment improves as stock rises 31%

Ocuphire Pharma, Inc. Just Beat Revenue Estimates By 42%

Ocuphire Pharma, Inc. Announces FDA Acceptance of New Drug Application and PDUFA Date of September 28, 2023 for Nyxol Eye Drops for Reversal of Mydriasis

Consensus revenue estimates increase by 45%

Ocuphire Pharma, Inc. Announces Topline Results from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy and Plans for End-of-Phase 2 Meeting with FDA

We're Keeping An Eye On Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Rate

Price target decreased by 12% to US$20.40

Ocuphire Pharma Announces First Patient Enrolled in Vega-2 Pivotal Phase 3 Trial of Nyxol® in Presbyopia

High number of new and inexperienced directors

マネジメント基準チェック /24